Piperacillin and Tazobactam for Injection Recalled for Lack of Sterility Assurance
The FDA is recalling 169,520 vials of Piperacillin and Tazobactam injectable antibiotic due to lack of assurance of sterility. The affected vials were distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of injectable antibiotic vials due to lack of assurance of sterility, a risk-of-harm product where injury has not yet been reported.
Plain-English summary
Astral SteriTech Private Ltd. is recalling all lots of Piperacillin and Tazobactam for Injection, USP 2.25 g per vial (NDC 70594-078-02) due to a lack of assurance of sterility. A total of 169,520 vials have been affected by this recall.
The affected vials were distributed nationwide throughout the United States. This is a prescription injectable antibiotic product.
Healthcare providers and individuals who have received or may be in possession of this product should consult with their healthcare provider regarding their treatment and use of the product. The FDA recommends that affected products not be used.
All recalled vials are within their expiration dates. Any adverse events or health concerns related to this product should be reported to the FDA.
The recalled product
- Product
- Piperacillin and Tazobactam for Injection, USP 2.25 g per vial,s Rx only, Manufactured for: Xellia Pharmaceuticals USA, LLC, Buffalo Grove, IL 60089, NDC 70594-078-02
- Manufacturer
- Astral SteriTech Private Ltd.
- Category
- Drug — Injectable Antibiotic
- Hazard
- lack-of-sterility
- contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots within expiry.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27